Skip to main content

Advertisement

SpringerLink
Log in

Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Clostridium difficile infection (CDI) is an important public health problem in hospitalized patients. Patients with cirrhosis are particularly at risk of increased associated morbidity, mortality, and healthcare utilization from CDI.

Aim

The aim of this study was to assess the pharmacoeconomic impact of CDI screening on hospitalized patients with cirrhosis.

Methods

A Markov model was used to compare costs and outcomes of two strategies for the screening of CDI. The first strategy consisted of screening all patients for CDI and treating if detected (screening). In the second strategy, only patients found to have symptomatic CDI were treated (no screening). The probability of underlying CDI prevalence, symptomatic CDI infection, and likelihood of recurrent infection were varied in a sensitivity analysis. The costs of antibiotics and hospitalization were also assessed. Differences in outcome were expressed in ratio of the total costs associated with screening to the total costs associated without screening.

Results

The results of our model showed that screening for CDI was consistently associated with improved healthcare outcomes and decreased healthcare utilization across all variables in the one- and two-way sensitivity analyses. Using baseline assumptions, the costs associated with the no screening strategy were 3.54 times that of the screening strategy. Moreover, the mortality for symptomatic CDI was lower in the screening strategy than the no screening strategy.

Conclusion

The screening strategy results in less healthcare utilization and improved clinical outcomes. Screening for CDI measures favorably.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J Med. 2008;359:1932–1940.

    Article  CAS  PubMed  Google Scholar 

  2. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile–associated diarrhea: a review. Arch Intern Med. 2001;161:525–533.

    Article  CAS  PubMed  Google Scholar 

  3. Niemczyk M, Leszczyniski P, Wyzgal J, Paczek L, Krawczyk M, Luczak M. Infections caused by Clostridium difficile in kidney or liver graft recipients. Ann Transpl. 2005;10:70–74.

    Google Scholar 

  4. Rodemann JF, Dubberke ER, Reske KA, da Seo H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–344.

    Article  PubMed  Google Scholar 

  5. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010;105:106–113.

    Article  PubMed  Google Scholar 

  6. Sundaram V, May FP, Manne V, Saab S. Effects of Clostridium difficile infection in patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2014;12:1745–1752.

    Article  PubMed  Google Scholar 

  7. Bajaj JS, O’Leary JG, Reddy R, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis. Hepatology. 2012;56:2328–2335.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults. Infect Control Hosp Epidemiol. 2010;31:431–455.

    Article  PubMed  Google Scholar 

  9. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–498.

    Article  CAS  PubMed  Google Scholar 

  10. Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med. 1993;94:313–328.

    Article  CAS  PubMed  Google Scholar 

  11. Calfee DP, Salgado CD, Classen D, et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29:562–580.

    Article  Google Scholar 

  12. Jain R, Kralovic SM, Evans ME, et al. Veterans AFFAIRS initiative to prevent methicillin-resistance Staphylococcus aureus infections. N Engl J Med. 2011;364:1419–1430.

    Article  CAS  PubMed  Google Scholar 

  13. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis.. 2007;13:1840–1846.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Harbarth S. Control of endemic methicillin-resistant Staphylococcus aureus–recent advances and future challenges. Clin Microbiol Infect. 2006;12:1154–1162.

    Article  CAS  PubMed  Google Scholar 

  15. Zanetti G, Goldie SJ, Platt R. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis. 2001;7:820–827.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Coia E, Leanord AT, Reilly J. Screening for methicillin resistant Staphylococcus aureus (MRSA): who, when, and how? BMJ. 2014;348:g1697.

    Article  PubMed  Google Scholar 

  17. Novak-Weekley S, Hollingsworth MH. Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of Clostridium difficile infection. Clin Vaccine Immunol. 2008;15:575–578.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–397.

    Article  CAS  PubMed  Google Scholar 

  19. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990;336:97–100.

    Article  CAS  PubMed  Google Scholar 

  20. Samore M, DeGirolami P, Tlucko A, Lichtenberg D, Melvin Z, Karchmer A. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994;18:181–187.

    Article  CAS  PubMed  Google Scholar 

  21. Vivian L, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693–1703.

    Article  Google Scholar 

  22. Rubin M, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum. 1995;38:350–354.

    Article  CAS  PubMed  Google Scholar 

  23. Saab S, Choi YM, Rahal H, Li K, Tong M. Trends in viral hepatitis cost-effectiveness studies. Am J Managed Care. 2012;18:790–798.

    Google Scholar 

  24. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child–Pugh class A cirrhosis. Am J Med. 1996;101:422–434.

    Article  CAS  PubMed  Google Scholar 

  25. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–690.

    Article  PubMed  Google Scholar 

  26. Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl. 2003;9:672–681.

    Article  PubMed  Google Scholar 

  27. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–1172.

    Article  CAS  PubMed  Google Scholar 

  28. Coon Thompson J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98:1166–1175.

    Article  Google Scholar 

  29. Cucchetti A, Trevisani F, Cescon M, et al. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian liver cancer population. J Hepatol. 2012;56:1089–1096.

    Article  PubMed  Google Scholar 

  30. Ruelas-Villavicencio AL, Vargas-Vorácková F. In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective? Ann Hepatol. 2004;3:152–159.

    PubMed  Google Scholar 

  31. Arguedas MR, Heudebert GR, Eloubeidi MA, Abrams GA, Fallon MB. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol. 2002;97:2441–2452.

    Article  PubMed  Google Scholar 

  32. Spiegel BM, Targownik L, Dulai GS, Karsan HA, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost-effective? Hepatology. 2003;37:366–377.

    Article  PubMed  Google Scholar 

  33. Imperiale TF, Klein RW, Chalasani N. Cost effectiveness analysis of variceal ligation vs. beta blockers for primary prevention of variceal bleeding. Hepatology. 2007;45:870–878.

    Article  PubMed  Google Scholar 

  34. Saab S, DeRosa V, Nieto J, Durazo F, Han S, Roth B. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. Am J Gastroenterol. 2003;98:763–770.

    Article  PubMed  Google Scholar 

  35. Mittal C, Hassan S, Arshad S, et al. Clostridium difficile infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. Am J Transpl. 2014;8:1901–1907.

    Article  Google Scholar 

  36. Shen EP, Surawicz CM. Current treatment options for severe Clostridium difficile—associated disease. Gastroenterol Hepatol. 2008;4:134–139.

    Google Scholar 

  37. Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis. 2012;55:351–357.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Musa S, Moran C, Rahman T. Clostridium difficile infection and liver disease. J Gastrointestin Liver Dis. 2010;3:303–310.

    Google Scholar 

  39. Red Book Online. Micromedex 2.0. http://www.micromedexsolutions.com/micromedex2/librarian/redbook. Accessed August 26, 2014.

  40. Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Dis. 2013;15:798–804.

    Article  CAS  PubMed  Google Scholar 

  41. Manek K, Williams V, Callery S, Daneman N. Reducing the risk of severe complications among patients with Clostridium difficile infection. Can J Gastroenterol. 2011;25:368–372.

    PubMed Central  PubMed  Google Scholar 

  42. Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol. 2013;51:869–873.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:381–390.

    Article  PubMed  Google Scholar 

  44. Lanzas C, Dubberke ER. Effectiveness of screening hospital admissions to detect asymptomatic carriers of Clostridium difficile: a modeling evaluation. Infect Control Hosp Epidemiol. 2014;35:1043–1050.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Naadir Jamal for his administrative assistance.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

    Sammy Saab

  2. Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA

    Sammy Saab, Theodore Alper, Ernesto Sernas & Paridhima Pruthi

  3. Gastroenterogy Associates, Fresno, CA, USA

    Mikhail A. Alper

  4. Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Vinay Sundaram

  5. Pfleger Liver Institute, 200 Medical Plaza, Suite 214, Los Angeles, CA, 90095, USA

    Sammy Saab

Authors
  1. Sammy Saab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theodore Alper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ernesto Sernas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paridhima Pruthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mikhail A. Alper
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vinay Sundaram
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sammy Saab.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saab, S., Alper, T., Sernas, E. et al. Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis. Dig Dis Sci 60, 3124–3129 (2015). https://doi.org/10.1007/s10620-015-3707-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3707-8

Keywords

Search

Navigation